When should octreotide be used in short bowel syndrome and why?

• A. In early adaptation stage to promote adaptation
• B. For small-volume stool losses with good fluid balance
• C. For large-volume stool losses with fluid and electrolyte management problematic; avoid early adaptation due to cholelithiasis risk; effects are short lasting and not shown to improve absorption or eliminate parenteral nutrition
• D. Only after parenteral nutrition is discontinued

Answer: (C)

Octreotide helps reduce intestinal secretions and slow transit, which can lower high-volume stool output in short bowel syndrome. This makes it a useful tool when there are large-volume losses that threaten fluid and electrolyte balance, providing a window to stabilize the patient and manage parenteral nutrition. However, its effects are not long-lasting and it does not improve absorption or eliminate the need for PN. It also carries a risk of cholelithiasis with longer use, which is particularly concerning during the early adaptation period when the bowel is trying to adapt. Because of these factors, octreotide is best reserved for patients with very high output and problematic fluid/electrolyte management, not for early adaptation, not for small-volume losses with good balance, and not solely after PN has been discontinued.